NCT04243109终止2 期
Pilot Study (Phase II) of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib
Maimónides Biomedical Research Institute of Córdoba1 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2017年2月23日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Best response
研究概览
简要总结
Clinical trial with a pharmaceutical specialty in a new combination.
Pomalidomide in combination with dexamethasone is indicated in the treatment of adult patients with multiple treatment-resistant or relapsing myeloma who have received at least two previous treatments, including lenalidomide and bortezomib, and who have experienced a disease progression in the last treatment.
The combination of Pomalidomide with Cyclophosphamide at metronomic doses (Very low doses) and Dexamethasone is tested in this clinical situation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient over 18 years of age and who meets criteria 2 and / or
- •Patient diagnosed with symptomatic Multiple Myeloma according to standard criteria.
- •Patients with symptomatic multiple myeloma in relapse / refractory after having received treatment with at least two cycles that include Bortezomib and with at least two cycles that include Lenalidomide, whether combined in the same therapeutic scheme or as part of different chemotherapy schemes.
- •Patients with MM with measurable disease, defined as the presence of monoclonal component of at least 0.5 g / dL in serum or at least 0.2 g / d in urine, or in those without measurable disease the presence of altered light chain radius at the time of entry into the study.
- •Patients with good general condition defined as ECOG ≤
- •The patient must understand the written informed consent and sign it of his own accord.
- •The patient must be able to meet all scheduled visits and other requirements.
- •Laboratory Criteria: Patients must present the following counts:Absolute neutrophils: ≥1000 / μL, Platelet Count: ≥50,000 / μL, Hemoglobin:> 8 gr / dL, Total bilirubin: <2 x upper limit of normal, AST and ALT: <3 x Upper limit of normal, Serum potassium: within the limits of normality.
- •Women of childbearing age should have a negative pregnancy test.
- •The male patient included in the trial must commit to always use a latex condom during any sexual contact with women of childbearing age, even if they have undergone a successful vasectomy.
排除标准
- •Any concomitant disease, laboratory alteration or psychiatric disorder that may presuppose the subject's inability to sign the IC.
- •PS> 3 according to the ECOG scale.
- •Previous history of non-hematologic malignancies, unless the patient has been free of the disease for ≥ 5 years. Exceptions include the following: Basal cell carcinoma of the skin, Squamous cell carcinoma of the skin, Carcinoma in situ of the cervix, Carcinoma in situ of the breast.
- •Patients who are unable or unwilling to undergo antithrombotic therapy.
- •Known positive serology for human immunodeficiency virus HIV or active infectious hepatitis, type B, or C.
- •Depressed heart function, or clinically significant heart disease
- •Severe hypercalcemia
- •Major surgical interventions within 15 days prior to inclusion or not having recovered from their side effects.
- •Any serious medical condition, including laboratory alterations that cause the patient to take an unacceptable risk if participating in this study or that may interfere with the interpretation of the study data.
- •Patients treated with any investigational drug in the previous 28 days.
- •Any severe medical condition, abnormality in laboratory tests or any psychiatric illness that prevents the signing of written consent.
- •Pregnant or breastfeeding women.
- •Known hypersensitivity to drugs or compounds of biological or chemical composition similar to those of the study.
- •Plasma Cell Leukemia
研究组 & 干预措施
Pomalidomide + Cyclophosphamide + Dexamethasone
Experimental
Treatment Phase: Combination of Pomalidomide, Cyclophosphamide and Dexamethasone, days 1-21 every 4 weeks (28 day cycles), up to a total of 8 cycles:
- Pomalidomide: Treatment with Pomalidomide 4 mg / day 1-21 days in 28-day cycles is started.
- Cyclophosphamide: Cyclophosphamide will be administered 15 mg / day, days 1-28 in 28-day cycles.
- Dexamethasone: Dexamethasone will be administered 40 mg / day, days 1, 8, 15 and 22 in 28-day cycles.
Maintenance Phase: Combination of Pomalidomide and Dexamethasone. The last doses prescribed in the previous cycle will be maintained.
干预措施: Pomalidomide + Cyclophosphamide + Dexamethasone (Drug)
结局指标
主要结局
Best response
时间窗: Every 28 days (each cycle is 28 days) from randomization until progression or withdrawal of the subject, whichever came first, assessed up to 60 months.
Evaluate the best response rate based on the criteria of the International Myeloma Working Group of the following responses at the end of each cycle or during the maintenance period.
次要结局
- Duration of Response(Every 28 days (each cycle is 28 days) from randomization until progression or withdrawal of the subject, whichever came first, assessed up to 60 months.)
- Time to Progression(Every 28 days (each cycle is 28 days) from randomization until progression or withdrawal of the subject, whichever came first, assessed up to 60 months.)
- Progression Free Survival(Every 28 days (each cycle is 28 days) from randomization until progression or withdrawal of the subject, whichever came first, assessed up to 60 months.)
- Tolerability of the study medication(Every 28 days (each cycle is 28 days) from randomization until progression or withdrawal of the subject, whichever came first, assessed up to 60 months.)
- Immune system evaluation of metronomic chemotherapy activity(At baseline and before the beginning of the 2nd, 4th, 6th and 8th treatment cycle (each cycle is 28 days))
- Time to Response(Every 28 days (each cycle is 28 days) from randomization until progression or withdrawal of the subject, whichever came first, assessed up to 60 months.)
- Angiogenesis markers of metronomic chemotherapy activity 2(At baseline and before the beginning of the 2nd, 4th, 6th and 8th treatment cycle (each cycle is 28 days))
- Global Survival(Every 28 days (each cycle is 28 days) from randomization until progression or withdrawal of the subject, whichever came first, assessed up to 60 months.)
- Angiogenesis markers of metronomic chemotherapy activity(At baseline and before the beginning of the 2nd, 4th, 6th and 8th treatment cycle (each cycle is 28 days))
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple MyelomaMultiple Myeloma-Light Chain OnlyRecurrent Plasma Cell MyelomaRefractory Plasma Cell MyelomaNCT01946152M.D. Anderson Cancer Center21
已完成
2 期
Pomalidomide and Dexamethasone (PDex) in AL AmyloidosisPrimary Amyloidosis of Light Chain TypeNCT01510613Fondazione IRCCS Policlinico San Matteo di Pavia28
已完成
2 期
An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)Multiple MyelomaNCT02654132Bristol-Myers Squibb117
终止
1 期
Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple MyelomaMultiple Myeloma in RelapseNCT01889420New Mexico Cancer Care Alliance1
已完成
2 期
Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)Multiple MyelomaNCT01745640University Hospital, Lille63